Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Autor: Meghan C. Thompson, Rosemary A. Harrup, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey J. Pu, Michael Y. Choi, Paul M. Barr, John N. Allan, Martin Šimkovič, Lori Leslie, Joanna Rhodes, Elise A. Chong, Manali Kamdar, Alan Skarbnik, Frederick Lansigan, Brittany McCall, Khalid Saja, Martin J. S. Dyer, Harriet S. Walter, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, Juliana Biondo, Kavita Sail, Beenish S. Manzoor, Richard Furman, Kurt S. Bantilan, Andre Goy, Tatyana Feldman, Dominic Labella, Stephen J. Schuster, Jae Park, Lia Palomba, Andrew Zelenetz, Toby A. Eyre, Arnon P. Kater, John F. Seymour, Anthony R. Mato

Publikováno v: Blood, 6(15), 4553-4557. American Society of Hematology
Blood advances, 6(15), 4553-4557. American Society of Hematology
Thompson, M C, Harrup, R A, Coombs, C C, Roeker, L E, Pu, J J, Choi, M Y, Barr, P M, Allan, J N, Simkovi, M, Leslie, L, Rhodes, J, Chong, E A, Kamdar, M, Skarbnik, A, Lansigan, F, McCall, B, Saja, K, Dyer, M J S, Walter, H S, Lefebure, M, Thadani-Mulero, M, Boyer, M, Biondo, J, Sail, K, Manzoor, B S, Furman, R, Bantilan, K S, Goy, A, Feldman, T, Labella, D, Schuster, S J, Park, J, Palomba, L, Zelenetz, A, Eyre, T A, Kater, A P, Seymour, J F & Mato, A R 2022, ' Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen ', Blood, vol. 6, no. 15, pp. 4553-4557 . https://doi.org/10.1182/bloodadvances.2022007812

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5788d2dcc76be1604266c786b4beeb47
https://research.vumc.nl/en/publications/dcf1cfe8-7b8c-4df5-b481-6746476ba1c1

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

Autor: David T Yeung, Andrew Grigg, Naranie Shanmuganathan, Ann Christine Solterbeck, Deborah L. White, Susan Branford, Nicholas Viiala, Philip Arthur Rowlings, Anthony K Mills, Jake Shortt, Campbell Tiley, David M Ross, David Kipp, Rosemary Anne Harrup, Ilona Cunningham, John Kwan, Richard Eek, Howard Mutsando, Ken-Soon Tan, Kate Burbury, Matthew P.F. Wright, Timothy P. Hughes, On Behalf of the ALLG

Publikováno v: Blood. 134:4150-4150

Dasatinib treatment leads to excellent molecular responses in chronic phase chronic myeloid leukemia (CP-CML). Pleural effusions, an adverse event related dasatinib treatment, may lead to intolerance and drug discontinuations. Strategies aimed at min

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d2b6bfdc539e0da21e23ec20e05f6901
https://doi.org/10.1182/blood-2019-127619